Related Experiment Video
Updated: Mar 5, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Andreas Link1, Tarek Ayadhi, Michael Böhm
1Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, D-66421Homburg/Saar, Germany. link@med-in.uni-saarland.de
Insights
Rosuvastatin rapidly reduces inflammation in acute coronary syndrome (ACS) patients by modulating T-cell activation. These immunomodulatory effects occur quickly, independent of lipid-lowering, suggesting a direct anti-inflammatory mechanism for statins in ACS.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Statins (HMG-CoA reductase inhibitors) are known to reduce cardiovascular events in patients with coronary artery disease and acute coronary syndrome (ACS).
- The speed and mechanism of statin's beneficial effects in ACS, particularly concerning their immunomodulatory properties versus lipid-lowering, remain unclear.
Purpose of the Study:
- To investigate the rapid immunomodulatory effects of rosuvastatin in patients with ACS.
- To determine if these effects are linked to lipid-lowering or occur independently.
Main Methods:
- A randomized trial involving 35 patients with troponin-positive ACS treated with rosuvastatin (20 mg/day) or placebo.
- Measurement of lymphocyte intracellular cytokine production (assessing anti-inflammatory effects) at baseline, day 1, day 3, and day 42.
Main Results:
- Rosuvastatin significantly reduced plasma pro-inflammatory cytokines TNF-alpha and IFN-gamma within 72 hours compared to placebo.
- Rosuvastatin rapidly decreased TNF-alpha and IFN-gamma production in stimulated T-lymphocytes at 72 hours.
- The study observed a significant inhibition of the Th-1 immune response at 72 hours with rosuvastatin treatment.
Conclusions:
- Rosuvastatin demonstrates rapid immunomodulatory effects in patients with ACS.
- These effects involve the modulation of T-cell activation and Th-1 immune response.
- The findings suggest a direct anti-inflammatory action of rosuvastatin in ACS, potentially independent of its lipid-lowering capacity.
Aims:
HMG-CoA reductase inhibitors (statins) reduce cardiovascular mortality and morbidity in patients with stable coronary artery disease as well as acute coronary syndrome (ACS). It is unclear how rapidly the beneficial effects of statins occur in patients with ACS and whether these drug properties are related to lipid lowering.
Methods And Results:
Patients with troponin-positive ACS (n=35) were randomized to 20 mg/day rosuvastatin therapy or to placebo treatment. Anti-inflammatory effects of rosuvastatin measured by lymphocyte intracellular cytokine production were taken before initiation of treatment and on days 1, 3, and 42. Compared with placebo, rosuvastatin treatment significantly reduced plasma concentrations of pro-inflammatory cytokines TNF-alpha and IFN-gamma at 72 h. Rosuvastatin also induced a rapid and significant reduction of TNF-alpha and IFN-gamma production in stimulated T-lymphocytes at 72 h. When compared with placebo, rosuvastatin inhibited the Th-1-immune response measured at 72 h.
Conclusion:
Rosuvastatin exerts rapid immunomodulatory effects on the level of T-cell activation in patients with ACS.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:27Coronary Artery Disease V: Interprofessional Care
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents